



BOB RILEY
Governor

Alabama Medicaid Agency

501 Dexter Avenue
P.O. Box 5624
Montgomery, Alabama 36103-5624

www.medicaid.state.al.us
e-mail: almedicaid@medicaid.state.al.us
Telecommunication for the Deaf: 1-800-253-0799
1-800-362-1504 (334) 293-5500



MIKE LEWIS
Acting Commissioner

November 21, 2003

Dear Pharmaceutical Manufacturer:

This correspondence is to provide you with written notification that one or more of your products in the classes listed below is scheduled to be reviewed at the December 10, 2003 meeting of the Pharmacy and Therapeutics Committee. The meeting will begin at 1:00 p.m. and will be held at the Alabama State Capitol Auditorium located in Montgomery, AL. All meetings of this committee are open to the public.

Drug classes scheduled for review:

Antihyperlipidemics:

- HMG-CoA Reductase Inhibitors
- Fibric Acid Derivatives
- Niacin and Niacin Combinations

CNS Stimulants - ADHD Agents (only Rapid Onset/Long Duration Agents)

Antihypertensives:

- Beta-Adrenergic Blockers
- Calcium Channel Blockers
- Diuretics
- Hypotensive Agents (single-entity and combination products)

Strattera

Written notification of your intent to make an oral presentation at this meeting must be received by Medicaid no later than Monday, November 10, 2003. Please refer to the Medicaid web site for further information on the policies and operating procedures for the Pharmacy and Therapeutics Committee meetings.

Please contact the Medicaid Pharmacy Program at (334) 242-5050 if you should have questions regarding this notice.

Sincerely,

Louise F. Jones
Pharmacy Director